- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00855413
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
CID 0821 - Pilot Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected Antiretroviral Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Purpose: This is a pilot study to evaluate HIV viremia and persistence in acutely HIV infected antiretroviral naïve patients treated with Darunavir/ritonavir and Etravirine
Participants: 20 participants, age 18 and older, HIV infected, antiretroviral naïve patients
Procedures (methods): ARV treatment with Darunavir/ritonavir and Etravirine,
Optional studies:
Genital secretion samples, Cerebrospinal fluid samples, Leukapheresis, Endoscopy/colonoscopy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Study Design
This is a multicenter, single arm, 48-week open-label pilot study of DRV/R & ETR in acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. If baseline resistance is detected after treatment begins (e.g. evidence of pre-existing baseline resistance (genotypic or phenotypic) that may adversely affect the efficacy of the study regimen), the patient may elect to alter treatment as per best clinical practice. The new regimen will not be provided by the study, but will be obtained for the participant through available clinical resources.
After patients are identified with acute HIV infection, they will be offered the opportunity to participate in the study. Patients will also be offered the opportunity to co-enroll in CHAVI 001 and 012, studies that follow the virological and immunological response of patients with AHI, regardless of the initiation of ART. An overall consent form will be signed for study participation, and separate informed consents with signatures will be obtained for optional studies. Patients will be eligible for participation after signing the overall consent - agreeing to participate in studies of other compartment specimens is not required for enrollment. At the initial visit, patient eligibility will be confirmed with appropriate laboratory testing (see "STUDY POPULATION"). When eligibility is verified, entry laboratory studies will be obtained, and the participants will be started on DRV/r, and ETR. All participants will be followed at regular intervals thereafter as specified in the schedule of evaluations. Participants meeting criteria for virologic failure will be offered the opportunity to switch to the best available regimen as selected by their HIV provider.
Hypothesis
Combination therapy with DRV/R & ETR will suppress plasma viremia and improve immunologic function in antiretroviral (ART)-naïve, acutely HIV-infected (AHI) patients, and will limit replication in HIV-1 cellular compartments.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- The University of North Carolina - Chapel Hill
-
Durham, North Carolina, Förenta staterna, 27707
- Duke University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Documentation of Acute HIV Infection as defined above.
- Men and women age ≥18 years.
- Participants will be ART naïve, defined as ≤14 days of antiretroviral treatment at any time prior to entry. The only exceptions are: Post-exposure prophylaxis (PEP) provided the patient was documented as HIV-1 negative at least 3-6 months after completion of the PEP treatment.
- Screening HIV-1 RNA >1,000 copies/mL obtained within 30 days at study entry.
- Lab values obtained within 30 days prior to study entry:
- Absolute neutrophil count >500/mm3
- Hemoglobin > 8.5 g/dL for men and > 8.0 g/dL for women
- Platelet count >50,000/mm3
- AST (SGOT) ≤2.5 x ULN
- ALT (SGPT) ≤2.5 x ULN
- Total bilirubin <2.5 x ULN
Calculated creatinine clearance (Cockcroft-Gault formula) > 30mL/min:
- CrCl = (140-age) x body weight (kg) (x 0.85 if female)
- Serum creatinine [mg/dL] x (72)
- For women of reproductive potential, a negative serum or urine pregnancy test within 7 days prior to initiating antiretroviral study medications. Reproductive potential is defined as females who have reached menarche and have not been post-menopausal for at least 24 consecutive months, or have not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or salpingotomy). Acceptable documentation of surgical sterilization includes patient-reported history.
- If participating in sexual activity that could lead to pregnancy, female study patients must use at least one form of contraception, which could consist only of a barrier method. All patients must continue to use contraception for 6 weeks after stopping the study medications. Acceptable methods of contraception include: condoms (male or female) with or without spermicidal agent, diaphragm or cervical cap with spermicide, or IUD. Female volunteers not of reproductive potential are not required to use contraception.
- Ability and willingness of patient to give written informed consent.
Exclusion Criteria:
- Women who are pregnant or breast-feeding.
- Women with a positive pregnancy test on enrollment or prior to study drug administration.
- Women of reproductive potential who are unwilling or unable to use acceptable methods to avoid pregnancy for the entire study period
Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry.
- Prednisone at a daily dose of 10 mg or less (physiologic replacement dose) is permitted.
- Known allergy/sensitivity to study drugs or their formulations.
- Difficulty swallowing capsules/tablets.
- Inability to communicate effectively with study personnel.
- Incarceration; prisoner recruitment and participation are not permitted.
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements or confound the analysis of study endpoints.
- Any active psychiatric illness including schizophrenia, severe depression, or severe bipolar affective disorder that, in the opinion of the investigator, could confound the analysis of the neurological examination or neuropsychological test results.
- Active brain infection (except for HIV-1), brain neoplasm, space-occupying brain lesion requiring acute or chronic therapy. Participants with any fungal meningitis, parasitic infection, or CNS lymphoma are excluded from participation.
- Serious illness requiring systemic treatment and/or hospitalization until patient either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry. NOTE: Oral candidiasis, vaginal candidiasis, mucocutaneous herpes simplex, and other minor illnesses (as judged by the site investigator) have no restriction.
- Known cardiac conduction disease.
- Prior treatment with any other experimental drug for any indication (within 30 days of initiating study treatment).
- Unable to discontinue any current medications that are excluded during study treatment.
- A life expectancy less than twelve months.
- Acute Viral Hepatitis, including, but not limited to, Hepatitis A, B, or C
- Chronic Hepatitis B Infection documented by a detectable serum Hepatitis B surface antigen (HBsAg) or plasma HBV DNA
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Darunavir/Ritonavir and Etravirine
Darunavir/Ritonavir 800 mg/100 mg orally once daily. ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen. |
800 mg orally once daily
Andra namn:
100 mg orally once daily
Andra namn:
200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Virologic Response
Tidsram: 24 weeks
|
Virologic response defined as plasma HIV RNA measurement <200 copies/mL at week 24
|
24 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants With Virologic Response
Tidsram: 48 weeks from enrollment
|
Virologic response to study treatment defined as plasma HIV RNA measurement <50 copies/mL at week 48
|
48 weeks from enrollment
|
Median Change in CD4 Cell Count From Week 0 to Week 24.
Tidsram: week 0, week 24
|
week 0, week 24
|
|
Median Change in CD4 Cell Count From Week 0 to Week 48.
Tidsram: 48 weeks from enrollment
|
48 weeks from enrollment
|
|
HIV RNA Levels Immediately Prior to Initiating Study Treatment.
Tidsram: HIV RNA level at enrollment
|
HIV RNA level at enrollment
|
|
Median Time to HIV RNA Suppression to <200 Copies/mL
Tidsram: From enrollment to the date of HIV RNA suppression, assessed up to Week 48
|
From enrollment to the date of HIV RNA suppression, assessed up to Week 48
|
|
HIV RNA Detection in Semen
Tidsram: From enrollment through 48 weeks
|
Total cumulative levels of HIV RNA detected in the semen of participants from enrollment through week 48.
|
From enrollment through 48 weeks
|
Number of Participants Who Stopped Study Treatment Due to Adverse Event or Intolerance
Tidsram: Enrollment to Week 48
|
Enrollment to Week 48
|
|
Adverse Events Possibly or Definitely Related to Study Treatment Through Week 48
Tidsram: Enrollment to week 48
|
Total number of adverse events observed that were possibly or definitely related to study treatment through week 48
|
Enrollment to week 48
|
Maximum Etravirine Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture
Tidsram: Week 4 and week 48
|
Week 4 and week 48
|
|
Minimum Etravirine Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture
Tidsram: Week 4 and week 48
|
Week 4 and week 48
|
|
Maximum Darunavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture
Tidsram: Week 4 and week 48
|
Week 4 and week 48
|
|
Minimum Darunavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture
Tidsram: Week 4 and week 48
|
Week 4 and week 48
|
|
Maximum Ritonavir Exposure in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture
Tidsram: Week 4 and Week 48
|
Week 4 and Week 48
|
|
Minimum Ritonavir Exposure Range in Cerebrospinal Fluid Among Participants Who Consented to an Optional Lumbar Puncture
Tidsram: Week 4 and week 48
|
Week 4 and week 48
|
|
Maximum Etravirine Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen
Tidsram: Weeks 0-4 and weeks 12, 48
|
Weeks 0-4 and weeks 12, 48
|
|
Minimum Etravirine Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen
Tidsram: Weeks 0-4 and weeks 12, 48
|
Weeks 0-4 and weeks 12, 48
|
|
Maximum Darunavir Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen
Tidsram: Weeks 0-4 and weeks 12, 48
|
Weeks 0-4 and weeks 12, 48
|
|
Minimum Darunavir Exposure Range in Semen Among Participants Who Consented to an Optional Collection of Semen
Tidsram: Weeks 0-4 and weeks 12, 48
|
Weeks 0-4 and weeks 12, 48
|
|
Maximum Ritonavir Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen
Tidsram: Weeks 0-4 and Weeks 12, 48
|
Weeks 0-4 and Weeks 12, 48
|
|
Minimum Ritonavir Exposure in Semen Among Participants Who Consented to an Optional Collection of Semen
Tidsram: Weeks 0-4 and Weeks 12, 48
|
Weeks 0-4 and Weeks 12, 48
|
|
Maximum Etravirine Exposure in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure
Tidsram: between Week 4-12 and between Weeks 36-48
|
between Week 4-12 and between Weeks 36-48
|
|
Minimum Etravirine Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure
Tidsram: between Week 4-12 and between Weeks 36-48
|
between Week 4-12 and between Weeks 36-48
|
|
Maximum Darunavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure
Tidsram: between Week 4-12 and between Weeks 36-48
|
between Week 4-12 and between Weeks 36-48
|
|
Minimum Darunavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure
Tidsram: between week 4-12 and between weeks 36-48
|
between week 4-12 and between weeks 36-48
|
|
Maximum Ritonavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure
Tidsram: between week 4-12 and between Weeks 36-48
|
between week 4-12 and between Weeks 36-48
|
|
Minimum Ritonavir Exposure Range in Ileal Tissue Among Participants Who Consented to an Optional Gut Biopsy Procedure
Tidsram: between week 4-12 and between weeks 36-48
|
between week 4-12 and between weeks 36-48
|
|
Number of Participants With HIV RNA Measurement Above the Limits of Detection in Cerebrospinal Fluid
Tidsram: Week 4 and Week 48
|
Week 4 and Week 48
|
|
Number of Participants With Neurocognitive Impairment at Baseline
Tidsram: Week 2 or 4
|
Week 2 or 4
|
|
Number of Participants With Neurocognitive Impairment at Week 24
Tidsram: Week 24
|
Week 24
|
|
Number of Participants With Neurocognitive Impairment at Week 48
Tidsram: Week 48
|
Week 48
|
|
Overall Neurocognitive Impairment Score at Week 2 or 4
Tidsram: Week 2 or 4
|
Neuropsychological performance was assessed at Week 2 or 4, Week 24 and Week 48 in the following measures: Premorbid/language (Wide Range Achievement Test 4 -Reading Subtest), Learning (HVLT-R, Hopkins Verbal Learning Test-Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency.
An overall summary score was created by averaging all tests.
Participants also completed the self-reported functional status Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS).
Best available demographically corrected normative data were utilized to create z scores.
A negative z score denotes below-average performance relative to a US normative comparison population.
A higher z score is a better outcome.
|
Week 2 or 4
|
Overall Neurocognitive Impairment at Week 24
Tidsram: Week 24
|
Neuropsychological performance was assessed at week 2 or 4, week 24 and week 48 in the following measures: Premorbid/language (Wide Range Achievement Test 4 -Reading Subtest), Learning (Hopkins Verbal Learning Test - Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency.
An overall summary score of neurocognitive functioning was created by averaging all tests.
Participants also completed Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS).
Best available demographically corrected normative data were utilized to create z scores.
A negative z score denotes below-average performance relative to a US normative comparison population.
A higher z score is a better outcome.
|
Week 24
|
Overall Neurocognitive Impairment at Week 48
Tidsram: Week 48
|
Neuropsychological performance was assessed at baseline (week 2 or 4), week 24 and week 48 in the following domain (measures): Premorbid/language (Wide Range Achievement Test (WRAT) 4 - Reading Subtest), Learning (HVLT-R, Hopkins Verbal Learning Test - Revised), Memory (HVLT-R), Speed of Processing (Trailmaking A (Army Individual Test Battery, 1944), 1974, Stroop color, Attention (WAIS-III Symbol Search; Stroop word, Fine motor, Executive (Trailmaking B, Stroop interference, Letter, Category Fluency.
An overall summary score of neurocognitive functioning was created by averaging all tests.
Participants also completed the self-reported functional status Patient's Assessment of Own Functioning Inventory (PAOFI) and the Activities of Daily Living Scale (ADLS).
Best available demographically corrected normative data were utilized to create z scores.
A negative z score denotes below-average performance relative to a US normative comparison population.
A higher z score is a better outcome.
|
Week 48
|
Change in Overall Neurocognitive Impairment From Baseline to Week 24 or 48
Tidsram: Baseline to Week 24 or 48
|
Change in overall z score from baseline to week 24 or 48.
A negative z score denotes below-average performance relative to a US normative comparison population.
A higher z score is a better outcome.
|
Baseline to Week 24 or 48
|
Correlation of HIV RNA Levels in CSF and Drug Levels With Neurocognitive Functioning
Tidsram: From enrollment through Week 48
|
From enrollment through Week 48
|
|
Correlation of Time to HIV RNA Levels <200 Copies/mL With Improvement in Neurocognitive Functioning From Baseline to Week 24 and 48
Tidsram: Baseline to Week 24 and 48
|
Baseline to Week 24 and 48
|
|
HIV RNA Detection in Ileal Biopsy Specimens
Tidsram: Weeks 4 and 48
|
Average HIV RNA detected in the ileal biopsy specimens per participant over weeks 4 and 48.
|
Weeks 4 and 48
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: David M Margolis, MD, University of North Carolina, Chapel Hill
- Huvudutredare: Cynthia Gay, MD, MPH, University of North Carolina, Chapel Hill
Publikationer och användbara länkar
Allmänna publikationer
- Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, McGee KS, Kerkau M, Sebastian J, Fiscus SA, Margolis DM, Hicks CB, Ferrari G, Eron JJ; Duke-UNC Acute HIV Infection Consortium. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011 Apr 24;25(7):941-9. doi: 10.1097/QAD.0b013e3283463c07.
- C Gay, O Dibben, A Stacey, N Gasper-Smith, M Liu, N Goonetilleke, G Ferrari, J Eron, C Hicks, A McMichael, B Haynes, P Borrow, M Cohen, the Duke-UNC CHAVI 001 Clinical Working Group. "Effect(s) of antiretroviral treatment on acute HIV infection." XVII International AIDS Conference, 2008 Abstract no. THPE0086.
- Gay CL, Neo DT, Devanathan AS, Kuruc JD, McGee KS, Schmitz JL, Sebastian J, Shaheen NJ, Ferrari G, McKellar M, Fiscus SA, Hicks CB, Robertson K, Kashuba ADM, Eron JJ, Margolis DM. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. AIDS. 2020 Nov 1;34(13):1923-1931. doi: 10.1097/QAD.0000000000002652.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- RNA-virusinfektioner
- Virussjukdomar
- Blodburna infektioner
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- Systemiskt inflammatoriskt svarssyndrom
- Inflammation
- Sjukdomsegenskaper
- Sepsis
- Långsamma virussjukdomar
- HIV-infektioner
- Infektioner
- Smittsamma sjukdomar
- Förvärvat immunbristsyndrom
- Viremia
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Proteashämmare
- Cytokrom P-450 CYP3A-hämmare
- Cytokrom P-450 enzymhämmare
- HIV-proteashämmare
- Virala proteashämmare
- Ritonavir
- Darunavir
- Etravirin
Andra studie-ID-nummer
- CID 0821
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
-
National Taiwan University HospitalAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
Boston Children's HospitalSterileCare Inc.Anmälan via inbjudanCentral Line komplikation | Central Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
National Taiwan University Hospital Hsin-Chu BranchAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
Kliniska prövningar på Darunavir
-
Shanghai Public Health Clinical CenterOkändCoronavirus | Lunginflammation, PneumocystisKina
-
Janssen-Cilag International NVAvslutadHIV-infektioner | Humant immunbristvirus | Förvärvat immunbristsyndromvirus | AIDS-virusStorbritannien, Belgien, Tyskland, Spanien, Portugal, Israel, Danmark, Ryska Federationen, Österrike, Ungern, Schweiz
-
Hamad Medical CorporationAvslutadLunginflammation | COVID | CoronavirusQatar
-
Janssen Research & Development, LLCAvslutad
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Avslutad
-
Therapeutic ConceptsJanssen Scientific Affairs, LLCOkänd
-
A.O. Ospedale Papa Giovanni XXIIISan Raffaele University Hospital, ItalyOkändHIV-infektionItalien
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...ViiV HealthcareAvslutad